IFF to launch latest well-characterized biopolymer Methanova at CPHI

By Liza Laws

- Last updated on GMT

© Getty Images
© Getty Images

Related tags CPHI Barcelona Pharmaceutical industry conference

IFF’s Pharma Solutions division is poised to introduce new products and investments at this year's CPHI being held in Barcelona. OSP was lucky enough to catch up with them before the event starting next week.

At the event, IFF will display its portfolio ​of low nitrate solutions for the pharmaceutical industry and hopes to provide visitors with a first-hand preview of its latest innovations, such as Methanova - a cell-compatible and filterable methylcellulose for the biotechnology industries. The team will also spotlight the company’s investments and strategic initiatives in sustainability, quality and reliability. 

OSP: Are you a regular attendee at CPHI? If so why.

Yes, IFF’s Pharma Solutions division is a regular attendee at CPHI. The tradeshow is a great opportunity for the team to provide its customers in the pharmaceutical, biotechnology, and biomedical industries with a first-hand preview of new products, investments and innovations that can support them with their polymer and formulation needs. 

OSP: Are you showcasing anything new?

At CPHI, IFF will launch Methanova, a cell-compatible and filterable methylcellulose for the biotechnology industry. It is suitable for use in cell culture media - enabling cell therapies for many advanced diseases - and 3D bioprinting, allowing for example, in-vitro drug testing models or 3D cell cultures. Built on decades of polymer science expertise, Methanova is the latest addition to the NovaMatrix portfolio of well-characterized biopolymers for the pharmaceutical, biotechnology, and biomedical industries.

A key highlight at the show will also be our low nitrite solutions, such as Avicel PH LN portfolio, a robust low nitrite microcrystalline cellulose (MCC) that lowers the risk of nitrosamine formation in finished drug products, catering to the needs of pharmaceutical manufacturers seeking excipients to support their nitrosamine risk mitigation plans.  

Visitors to the booth can also learn more about IFF’s Methocel family of water-soluble cellulose ethers.

OSP: What do they hope to achieve from this year’s event? 

Besides learning about the expansion of its portfolio to include low nitrite excipient solutions and biopolymer innovations, at this year’s event, IFF invites visitors to find out more about its sustainability ​objectives – including responsible sourcing programs, continuous reduction in its carbon footprint across operations, and innovative solutions that do more good for people and the planet and help enable customers to achieve their sustainability goals. 

OSP: Why people should stop by and see your client

IFF’s experts will be available at booth 4A10 to share with visitors how IFF can help them improve the bioavailability and commercial viability of oral drugs – whether they are looking for customization or innovation expertise to differentiate in their markets or reformulation support to address changing market dynamics. For example, they will share how the Pharma Solutions team continually evaluates processes and makes analytical advances to meet customers’ expectations in the field of nitrosamine-sensitive oral solid dosage forms.

In addition, IFF’s Pharma Solutions team will be on hand to discuss how the company ensures reliability, product quality, and flexibility in its raw materials with its supplier assessments. 

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more